The May eJournalClub of CJASN selection, "Efficacy and Tolerance of Urea Compared with Vaptans for Long-Term Treatment of Patients with SIADH" by Alain Soupart, MD and colleagues
Check it out at http://ejc.cjasn.org/phpBB3/
Tuesday, May 15, 2012
CJASN Journal Club
Posted by Kenar D Jhaveri( kidney 007) at 8:24 AM
Labels: ejournalclub, social media
Subscribe to: Post Comments (Atom)
- ► 2022 (18)
- ► 2021 (36)
- ► 2020 (32)
- ► 2019 (42)
- ► 2018 (57)
- ► 2017 (52)
- ► 2016 (45)
- ► 2015 (63)
- ► 2014 (95)
- ► 2013 (133)
- KDIGO Glomerular Disease Guidelines: ANCA vasculitis
- KDIGO Guidelines for Glomerular Diseases: LUPUS NE...
- KDIGO Guidelines for Glomerular Diseases: HSP
- Healthcare in India exposed!
- KDIGO Glomerular Diseases Guidelines: IgA Nephropathy
- KDIGO Guidelines for Glomerular diseases: Infectio...
- KDIGO Guidelines for Glomerular Diseases: MPGN
- KDIGO Guidelines for Glomerular Diseases: Membrano...
- KDIGO Guidelines for Glomerular Diseases: FSGS in ...
- KDIGO Guidelines for Glomerular Diseases 2012: Min...
- Clinical Case 56: Answers and Summary
- CJASN Journal Club
- IN THE NEWS: OBESITY and ORGAN POOL DONATION
- Geriatric Workforce Shortage: What can we learn?
- IN the NEWS: Intensive treatment during end of lif...
- eAJKD: Live NKF coverage
- IN THE NEWS:ACR Lupus Nephritis Guidelines
- New Updates from Nephro-Pathology.com
- Topic Discussion: Hyperkalemia in Bartter Syndrome
- IN THE NEWS: Treating Cast Nephropathy without tre...
- ▼ May (20)
- ► 2011 (370)
- ► 2010 (461)
Yes, Vaptans are expensive and have not shown to decrease mortality (see EVEREST study). Also there is an intrinsic risk of overcorrection with Vaptans. Several studies in animals have shown that urea is not only effective in correcting serum sodium concentration, but it is cheap and apparently it protects against osmotic demyelination syndrome. Urea has been shown to increase reaccumulation of myoinositol in brain cells. That is why there are a handful of cases of ODS in dialysis patientsReplyDelete